|
21.01.2025 17:45:00
|
Transgene to Participate in the Biomed Forum Investor Conference
Strasbourg (France), January 21, 2025, 5:45 PM CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by AllInvest Securities, this event will take place on February 4, 2025, in Paris.
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at: www.transgene.fr
Follow us on social media: X (formerly Twitter):
@TransgeneSA
— LinkedIn: @Transgene
Contacts
| Media: | Investors & Analysts: |
| Caroline Tosch | Lucie Larguier |
| Corporate and Scientific Communications Manager | Chief Financial Officer (CFO) |
| +33 (0)3 68 33 27 38 | Nadege Bartoli |
| communication@transgene.fr | Investor Relations Analyst and Financial Communications Officer |
| MEDiSTRAVA | +33 (0)3 88 27 91 00/03 |
| Frazer Hall/Sylvie Berrebi | investorrelations@transgene.fr |
| + 44 (0)203 928 6900 | |
| transgene@medistrava.com |
Disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Attachment
📈 Zitat: „Digitalisierung beginnt nicht bei der Technik – sie beginnt beim Menschen.“ 🔎
Wie gelingt eine erfolgreiche Verbindung zwischen Tradition und Innovation im Bankwesen? Und welche Rolle spielt eine starke Führungspersönlichkeit dabei? In dieser Ausgabe des BX Morningcall tauchen wir tief ein in die Zukunft des Schweizer Bankgeschäfts – gemeinsam mit Melek Ates, der neuen Leiterin für das Privat- und Firmenkundengeschäft bei der Bank WIR. Sie bringt nicht nur über 30 Jahre Bankerfahrung mit, sondern auch frische Impulse in einer Zeit des Umbruchs und der digitalen Transformation.
Im Gespräch mit François Bloch und David Kunz gibt Melek Ates spannende Einblicke in ihre Vision für die Bank WIR, ihre Perspektiven auf den Schweizer KMU-Markt und ihre ganz persönliche Führungsphilosophie. Es geht um mehr als nur Zahlen – es geht um Werte, Wandel und Weitblick. Was macht Genossenschaftsbanken wie die Bank WIR besonders? Wie gelingt die digitale Transformation in einem traditionell geprägten Sektor? Und warum stehen dabei immer die Menschen im Mittelpunkt?
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Transgene S.A. | 0.67 | 0.30% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI etwas leichter -- DAX fällt -- US-Börsen schwächer -- Asiens Börsen letztlich in RotDer heimische Aktienmarkt präsentiert sich am Donnerstag leicht nach unten. Der deutsche Leitindex tendiert abwärts. Die US-Börsen geben nach. Die Börsen in Asien zeigten sich am Donnerstag in Rot.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |